...
首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.
【24h】

HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.

机译:HPLC测定血浆二甲基精氨酸:方法验证和初步临床应用。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Asymmetric dimethylarginine (ADMA) has been suggested as a possible marker of endothelial dysfunction, and interest in its use in clinical practice is increasing. However, the potential role of symmetric dimethylarginine (SDMA) as an endogenous marker of renal function, has been less widely investigated. The aims of the present study were therefore to determine reference values for dimethylarginines in plasma after method validation, and to ascertain ADMA plasma concentrations in patients with disorders characterized by endothelial dysfunction; a further end-point was to investigate the relationship between SDMA plasma concentrations and estimated GFR (eGFR) as well as plasmatic creatinine in patients with chronic kidney disease (CKD). MATERIALS AND METHODS: HPLC with fluorescence detection was used for the determination of plasma dimethylarginines. To verify the clinical usefulness of ADMA and SDMA, values from 4 groups of patients at a high risk of cardiovascular complications as well renal dysfunction (chronic heart failure n=126; type II diabetes n=43; pulmonary arterial hypertension n=17; chronic kidney disease n=42) were evaluated, and compared with the reference values, obtained from 225 blood donors. RESULTS: The intra- and inter-assay CVs (<5.2%), the absolute and relative recoveries (96-106%) were highly satisfactory. ADMA levels were significantly elevated in all groups of patients compared with controls (p<0.001) with the exception of samples from patients with type II diabetes. SDMA levels were significantly elevated both in the patients with chronic kidney disease and in the patients with type II diabetes complicated by renal insufficiency, the values being closely correlated with both eGFR (R=0.740) and plasmatic creatinine (R=0.700). CONCLUSIONS: The findings made in the present study shows that ADMA levels are significantly increased in patients with diseases associated with endothelial dysfunction This molecule might, therefore, be used as a biochemical marker for the evaluation of endothelial function. Furthermore, the preliminary results reported suggest that SDMA might be a reliable marker of renal function, especially in peadiatric populations, for which the use of eGFR is not recommended.
机译:背景:不对称的二甲基精氨酸(ADMA)被认为是内皮功能障碍的可能标志物,并且在临床实践中对其使用的兴趣正在增加。但是,对称二甲基精氨酸(SDMA)作为肾功能的内源性标志物的潜在作用尚未得到广泛研究。因此,本研究的目的是确定方法验证后血浆中二甲基精氨酸的参考值,并确定具有内皮功能障碍的疾病患者的ADMA血浆浓度。另一个终点是研究慢性肾脏病(CKD)患者的SDMA血浆浓度与估计的GFR(eGFR)以及血浆肌酐之间的关系。材料与方法:HPLC荧光检测法测定血浆二甲基精氨酸。为了验证ADMA和SDMA的临床有效性,我们对4组心血管并发症和肾功能不全的高风险患者进行了评估(慢性心力衰竭n = 126; II型糖尿病n = 43;肺动脉高压n = 17;慢性评估肾脏疾病n = 42),并将其与从225个献血者获得的参考值进行比较。结果:批内和批间CV(<5.2%),绝对和相对回收率(96-106%)非常令人满意。与对照组相比,所有患者组中的ADMA水平均显着升高(p <0.001),但来自II型糖尿病患者的样品除外。在患有慢性肾脏疾病的患者和患有肾功能不全的II型糖尿病患者中,SDMA水平均显着升高,该值与eGFR(R = 0.740)和血浆肌酐(R = 0.700)密切相关。结论:本研究的结果表明,患有内皮功能障碍的疾病患者的ADMA水平显着增加。因此,该分子可以用作评估内皮功能的生化标记。此外,已报道的初步结果表明,SDMA可能是肾功能的可靠标记,尤其是在不建议使用eGFR的小儿人群中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号